My Account Log in

2 options

Medicare program integrity, CMS pursues many practices to address prescription drug fraud, waste, and abuse : report to the Chairman, Subcommittee on Health, Committee on Ways and Means, House of Representatives.

Online

Available online

View online

U.S. Government Documents Available online

View online
Format:
Book
Government document
Author/Creator:
United States. Government Accountability Office, author.
Contributor:
United States. Congress. House. Committee on Ways and Means. Subcommittee on Health, sponsoring body.
Language:
English
Subjects (All):
Centers for Medicare & Medicaid Services (U.S.)--Rules and practice.
Centers for Medicare & Medicaid Services (U.S.).
Medicare fraud--Prevention.
Medicare fraud.
Medication abuse--United States--Prevention.
Medication abuse.
Waste in government spending--United States.
Waste in government spending.
Medication abuse--Prevention.
United States.
Genre:
Internet resources.
Rules
Physical Description:
1 online resource (ii, 34 pages) : color illustrations
Other Title:
CMS pursues many practices to address prescription drug fraud, waste, and abuse
Medicare program integrity, Centers for Medicare and Medicaid Services' pursues many practices to address prescription drug fraud, waste, and abuse
Place of Publication:
[Washington, D.C.] : United States Government Accountability Office, 2014.
Summary:
Recent media reports and law enforcement actions have highlighted the problem of prescription drug fraud, waste, and abuse in the United States. Medicare, and the Part D prescription drug benefit, are susceptible to such fraud--a risk made greater by Medicare's size, scope, and complexity. GAO and others have raised questions about CMS's oversight of its activities to address fraud, waste, and abuse in Part D, as well as oversight of the contractors tasked with this work. GAO examined (1) practices for promoting prescription drug program integrity, and (2) the extent that CMS's oversight of Medicare Part D program integrity, including the program integrity contractors, reflects these practices. To develop a list of practices, GAO interviewed 14 stakeholder groups involved in various aspects of prescription drug program integrity, including provider, beneficiary, and anti-fraud groups; identified and reviewed related documents; and conducted a search of eight bibliographic databases that included peer-reviewed articles and government documents. GAO organized the practices based on the three categories of GAO's Fraud Prevention Framework. To determine how CMS's oversight reflects these practices, GAO analyzed agency documents, such as contracts, manuals, work products, and CMS audits of contractors; and interviewed agency officials.
Notes:
Title from title screen (viewed on September 15, 2016).
"October 2014."
"GAO-15-66."
Includes bibliographical references.
OCLC:
944264387

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Library Catalog Using Articles+ Library Account